Business context and reporting period
Phreesia, Inc. (NYSE: PHR) provides healthcare software for patient access, registration, payments and engagement, alongside communication services for life sciences and payer clients. This Form 10-K covers fiscal 2024, the year ended January 31, 2024—not a standalone calendar fourth quarter. Comparisons are with fiscal 2023.
Financial performance and liquidity
| Metric | FY2024 | FY2023 |
|---|---|---|
| Revenue | $356.3 million | $280.9 million |
| Operating loss | $136.5 million | $176.6 million |
| Net loss | $136.9 million | $176.1 million |
| Net loss per share, basic and diluted | $2.51 | $3.36 |
| Adjusted EBITDA (non-GAAP) | $(35.4) million | $(92.5) million |
| Cash from operating activities | $(32.4) million | $(90.1) million |
| Free cash flow (non-GAAP) | $(57.5) million | $(116.3) million |
| Cash and cash equivalents at year-end | $87.5 million | $176.7 million |
Revenue mix in FY2024 was subscription and related services $165.4 million (46% of revenue), payment processing $94.6 million (27%) and Network solutions $96.3 million (27%). Operating margin was approximately negative 38% versus negative 63% in FY2023. A rough contribution margin—revenue less cost of revenue and payment processing expense—was approximately 65% versus 61%; this is an analyst calculation, not a company-reported GAAP margin.
Average healthcare services clients increased 26% to 3,601. Patient payment volume rose 20% to $3.947 billion. Healthcare services revenue per average client declined about 1% to $72,215, while total revenue per average client increased about 1% to $98,944.
Current assets were $195.7 million and current liabilities $110.1 million at year-end (current ratio approximately 1.8). Finance lease liabilities and other debt totaled $11.5 million, including $3.1 million under a software financing agreement. The $50 million Capital One secured revolving facility had no borrowings outstanding; the company reported compliance with its covenants. Cash used in investing activities was $39.7 million and cash used in financing activities was $17.1 million.
Material changes versus FY2023
- Revenue grew 27%, with all three revenue categories increasing: subscription and related services 28%, payment processing 21% and Network solutions 31%.
- Net loss narrowed by $39.3 million, and Adjusted EBITDA loss narrowed by $57.1 million. Cash used in operations improved by $57.7 million; free cash flow remained negative.
- Research and development expense rose 23% to $112.3 million, while sales and marketing expense declined 3% to $147.0 million. Stock-based compensation expense was $71.6 million, up from $58.8 million.
- Cash declined by $89.2 million during FY2024. Phreesia acquired MediFind, Access and ConnectOnCall for total consideration of $60.2 million, including $35.3 million in stock and $10.0 million in deferred liabilities; acquisition cash paid net of cash acquired was $14.6 million.
- The company replaced its SVB revolver with a five-year, $50 million Capital One facility and recorded a $1.1 million debt-extinguishment loss.
Outlook, risks and unusual items
- Management said cash, normal-course cash generation and available borrowing capacity should fund operations for at least 12 months. The filing also says net losses and negative cash flows are expected to continue for at least the next year. It provides no specific revenue, earnings or cash-flow guidance.
- Management’s stated strategy is to add healthcare-services clients, expand product use among existing clients, develop new offerings and pursue partnerships or acquisitions, while seeking improved margins and profitability over time.
- Key risks include ongoing losses and cash consumption; competition, including from EHR and practice-management vendors; customer retention and concentration; long sales and implementation cycles; reliance on payment processors and other vendors; and privacy, cybersecurity, healthcare-law and communications-law compliance.
- The company cited macroeconomic and geopolitical uncertainty, including inflation, interest rates and conflicts affecting international contractors. It plans to transition certain India-based outsourced services to a new subsidiary beginning in FY2025.
- Management reported no cybersecurity incidents or threats that had materially affected, or were reasonably likely to materially affect, the company. It disclosed no pending legal proceeding expected to have a material adverse effect. KPMG issued unqualified audit opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Whether revenue growth, client additions and Network solutions expansion persist, and whether healthcare-services revenue per client recovers.
- How quickly operating losses and negative free cash flow narrow, and whether cash plus undrawn facility capacity remains adequate as acquisitions and operations are funded.
- Acquisition integration, deferred consideration payments and the expected contribution of MediFind, Access and ConnectOnCall.
- Payment-platform economics and exposure to processor concentration, card-network fees and potential interchange-rule changes.
- The impact of stock-based compensation and acquisition-related amortization on reported profitability, alongside the company’s non-GAAP measures.
- Whether the expected India operating transition proceeds as planned and whether privacy, cybersecurity and regulatory risks or related costs change.